{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:40:32Z","timestamp":1774899632058,"version":"3.50.1"},"reference-count":30,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T00:00:00Z","timestamp":1386892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:sec id=\"S1092852913000904_abs1\" sec-type=\"general\"><jats:title>Objective<\/jats:title><jats:p>The aim of this analysis was to compare the effects of 2 atypical antipsychotic agents, lurasidone (80 mg\/d or 160 mg\/d) and quetiapine XR (600 mg\/d), on daytime alertness, and to evaluate the effects of daytime sleepiness on treatment outcomes in patients with an acute exacerbation of schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000904_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Patients who met <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>, 4th edition, text revision (DSM-IV-TR) criteria for schizophrenia were randomized to 6 weeks of double-blind treatment with fixed doses of lurasidone 80 mg\/d (n = 125), lurasidone 160 mg\/d (n = 121), quetiapine XR 600 mg\/d (n = 119), or placebo (n = 121), all dosed once daily in the evening, with food. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000904_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Daytime sleepiness improved in the lurasidone and placebo-treated groups but worsened in the quetiapine XR treatment group when compared to placebo (p = 0.001) and to either dose of lurasidone (both p &lt; 0.01). Sedation associated with quetiapine XR treatment mediated an improvement in agitation [assessed by the Positive and Negative Syndrome Scale\u2014Excitement (PANSS-EC) subscale] and a worsening in functional capacity [assessed by the University of California\u2013San Diego (UCSD) Performance-Based Skills Assessment\u2014Brief Version (UPSA-B) total score]; these mediating relationships were not observed for the lurasidone or placebo treatment groups.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852913000904_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>In this 6-week double-blind study, treatment with lurasidone 80 mg or 160 mg, administered once daily in the evening, was associated with a reduction in daytime sleepiness similar in magnitude to placebo, while quetiapine XR 600 mg\/d was associated with a significant increase in daytime sleepiness, compared to both lurasidone dose groups and placebo. Daytime sleepiness was associated with improvement in agitation and worsening in functional capacity for quetiapine XR, but not lurasidone or placebo-treated patients.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852913000904","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T09:31:22Z","timestamp":1386927082000},"page":"197-205","source":"Crossref","is-referenced-by-count":37,"title":["Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia"],"prefix":"10.1017","volume":"19","author":[{"given":"Antony D.","family":"Loebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia O.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine B.","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei A.","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip D.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2013,12,13]]},"reference":[{"key":"S1092852913000904_ref21","first-page":"15","article-title":"International assessment of functional skills in people with schizophrenia: innovations in clinical neuroscience","volume":"8","author":"Harvey","year":"2011","journal-title":"Innov Clin Neurosci"},{"key":"S1092852913000904_ref13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2869.2000.0227a.x"},{"key":"S1092852913000904_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"S1092852913000904_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.08.003"},{"key":"S1092852913000904_ref10","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structural diagnostic psychiatric interview for DSM-IV and ICD-10 1996","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852913000904_ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.10.877"},{"key":"S1092852913000904_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283430a0e"},{"key":"S1092852913000904_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"S1092852913000904_ref24","first-page":"419","article-title":"Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists","volume":"74","author":"Witek","year":"1995","journal-title":"Ann Allergy Asthma Immunol"},{"key":"S1092852913000904_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00087-2"},{"key":"S1092852913000904_ref25","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.167346"},{"key":"S1092852913000904_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.07.039"},{"key":"S1092852913000904_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"S1092852913000904_ref27","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.180638"},{"key":"S1092852913000904_ref3","unstructured":"American Academy of Sleep Medicine (AASM). Driving Fact Sheet, December 2, 2009. http:\/\/www.aasmnet.org\/Resources\/Factsheets\/DrowsyDriving.pdf. Accessed July 26, 2012."},{"key":"S1092852913000904_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S1092852913000904_ref7","volume-title":"Handbook of Psychiatric Measures","author":"Johns","year":"2008"},{"key":"S1092852913000904_ref19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.psych.58.110405.085542"},{"key":"S1092852913000904_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.09.002"},{"key":"S1092852913000904_ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923030-00007"},{"key":"S1092852913000904_ref5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0804"},{"key":"S1092852913000904_ref17","doi-asserted-by":"publisher","DOI":"10.1080\/13803390802592458"},{"key":"S1092852913000904_ref28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.8.1482"},{"key":"S1092852913000904_ref18","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm014"},{"key":"S1092852913000904_ref4","unstructured":"Colten HR , Altevogt BM , eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academy of Sciences. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK19958. Accessed July 16, 2012."},{"key":"S1092852913000904_ref1","first-page":"18","article-title":"Atypical antipsychotics: sedation versus efficacy","volume":"69","author":"Kane","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S1092852913000904_ref8","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000490"},{"key":"S1092852913000904_ref29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.56.1.85"},{"key":"S1092852913000904_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.01.009"},{"key":"S1092852913000904_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2008.10.037"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852913000904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:03:41Z","timestamp":1555956221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852913000904\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,13]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1092852913000904"],"URL":"https:\/\/doi.org\/10.1017\/s1092852913000904","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,13]]}}}